Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Anti-Her2 Antibody-Drug Conjugates in 2016: R&D and Business Tracker for Antibody-Drug Conjugates - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates" report to their offering.

This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.

The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:

R&D and Technology Tracker:

- Pipeline changes

- Regulatory news

- Technology validations

- Manufacturing news

Business Tracker for:

- Company updates

- Collaboration

- Licensing

- Merger & acquisitions

- Financing

Clinical Trial Tracker:

- Scientific Publication Tracker

- Featured ADC Profile: MEDI4276

- Featured Company Profile: NBE Therapeutics

- Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates

Information about the anti-Her2 ADC pipeline is provided in a tabular format and fully referenced.

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.